Purpose

To determine the difference in time to recovery and healing of monkey pox lesions between people receiving Tecovirimat and those receiving placebo. People with severe cases of monkeypox will receive Tecovirimat and not placebo.

Category

IRB Number
20220654HU
NCT Number
-
Sponsor
-



Study Contact

Principal Investigator
Thomas Patterson

Irma Scholler
210-450-3150
scholler@uthscsa.edu



Eligibility

Eligible Ages
18-99
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

    Illness < 14 days before study entry, have at least 1 active (not scabbed) lesion

Exclusion Criteria

    Illness < 14 days before study entry, have at least 1 active (not scabbed) lesion


Study Design

Arm Groups